% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sahm:130464,
      author       = {F. Sahm$^*$ and D. Schrimpf$^*$ and A. Olar and C.
                      Koelsche$^*$ and D. Reuss$^*$ and J. Bissel and A. Kratz and
                      D. Capper and S. Schefzyk and T. Hielscher$^*$ and Q. Wang
                      and E. P. Sulman and S. Adeberg and A. Koch and A. F.
                      Okuducu and S. Brehmer and J. Schittenhelm and A. Becker and
                      B. Brokinkel and M. Schmidt and T. Ull and K. Gousias and A.
                      F. Kessler and K. Lamszus and J. Debus and C. Mawrin and
                      Y.-J. Kim and M. Simon and R. Ketter and W. Paulus and K. D.
                      Aldape and C. Herold-Mende and A. von Deimling$^*$},
      title        = {{TERT} {P}romoter {M}utations and {R}isk of {R}ecurrence in
                      {M}eningioma.},
      journal      = {Journal of the National Cancer Institute},
      volume       = {108},
      number       = {5},
      issn         = {1460-2105},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-05543},
      pages        = {djv377 -},
      year         = {2016},
      abstract     = {The World Health Organization (WHO) classification and
                      grading system attempts to predict the clinical course of
                      meningiomas based on morphological parameters. However,
                      because of high interobserver variation of some criteria,
                      more reliable prognostic markers are required. Here, we
                      assessed the TERT promoter for mutations in the hotspot
                      regions C228T and C250T in meningioma samples from 252
                      patients. Mutations were detected in 16 samples $(6.4\%$
                      across the cohort, $1.7\%,$ $5.7\%,$ and $20.0\%$ of WHO
                      grade I, II, and III cases, respectively). Data were
                      analyzed by t test, Fisher's exact test, log-rank test, and
                      Cox proportional hazard model. All statistical tests were
                      two-sided. Within a mean follow-up time in surviving
                      patients of 68.1 months, TERT promoter mutations were
                      statistically significantly associated with shorter time to
                      progression (P < .001). Median time to progression among
                      mutant cases was 10.1 months compared with 179.0 months
                      among wild-type cases. Our results indicate that the
                      inclusion of molecular data (ie, analysis of TERT promoter
                      status) into a histologically and genetically integrated
                      classification and grading system for meningiomas increases
                      prognostic power. Consequently, we propose to incorporate
                      the assessment of TERT promoter status in upcoming grading
                      schemes for meningioma.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals) / TERT protein, human
                      (NLM Chemicals) / Telomerase (NLM Chemicals)},
      cin          = {G380 / C060 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26668184},
      pmc          = {pmc:PMC4849806},
      doi          = {10.1093/jnci/djv377},
      url          = {https://inrepo02.dkfz.de/record/130464},
}